Curis Inc (CRIS) 2.88 $CRIS
Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting
GlobeNewswire - Wed Apr 22, 7:15AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced today data presented from in vitro and in vivo studies for CUDC-427, an antagonist of inhibitor of apoptosis (IAP) proteins, at the American Association for Cancer Research (AACR) 2015 Annual Meeting. CUDC-427 is being studied in a Phase 1 trial in patients with advanced solid tumors or lymphoma. Curis' collaborator, Aurigene Discovery Technologies Limited, also reported preclinical data on its interleukin-1 receptor association kinase-4 (IRAK-4) inhibitor program at AACR.
CRIS: 2.88 (+0.09), RDY: 56.58 (+0.30)
Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015
PR Newswire - Sat Apr 18, 7:00AM CDT
Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the American Associate of Cancer Research Annual Meeting (April 18-22 in Philadelphia, PA).
CRIS: 2.88 (+0.09)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 4:36PM CDT
MNK: 122.95 (-2.22), FARO: 44.64 (-0.93), MDVN: 128.88 (+0.29), CRIS: 2.88 (+0.09), E: 36.62 (+0.43), PH: 123.47 (+1.33), YOKU: 16.42 (-0.21), FXCM: 2.13 (+0.02), VSLR: 14.33 (+0.36), IGT: 19.88 (-0.02)
Biotech Stocks Technical Report -- Novavax, MannKind, Juno Therapeutics, Curis, and Ohr Pharma
PR Newswire - Thu Apr 16, 8:15AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.88 (+0.09), NVAX: 8.51 (+0.09), OHRP: 2.72 (+0.08), JUNO: 55.72 (-0.68), MNKD: 4.90 (-0.09)
Curis Announces Presentation of Data From CUDC-427 and IRAK-4 Programs at AACR Annual Meeting
GlobeNewswire - Tue Apr 14, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Curis scientists and its collaborator, Aurigene Discovery Technologies Limited, will present data from two programs at the Annual Meeting of American Association of Cancer Research (AACR) to be held April 18 - 22, 2015 in Philadelphia.
CRIS: 2.88 (+0.09), RDY: 56.58 (+0.30)
Curis' CUDC-907 an Orphan Drug for blood cancer
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 9:01AM CDT
CRIS: 2.88 (+0.09)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 8:18AM CDT
RESN: 3.77 (-0.06), HLF: 46.63 (-0.13), MHR: 2.34 (-0.07), NG: 3.56 (-0.07), CRIS: 2.88 (+0.09), GBSN: 4.98 (+1.44), QURE: 26.15 (-1.44), CYTX: 0.96 (-0.09), GAME: 6.85 (unch), BIND: 7.01 (-0.30), DGLY: 13.13 (+0.08), CAPN: 6.99 (-0.29)
Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Mon Apr 06, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead proprietary drug candidate, CUDC-907 for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL).
CRIS: 2.88 (+0.09)
Roth Capital Weighs In On 5 Biotech Stocks To Watch
TipRanks - at Seeking Alpha - Mon Apr 06, 4:02AM CDT
By Sarah Roden As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to "focus on names with definitive catalysts." Though the analyst rates 15 biotech stocks,...
CRIS: 2.88 (+0.09), GNVC: 2.86 (-0.11), CLDX: 28.95 (+1.08), BLRX: 2.12 (unch), KERX: 11.52 (-0.15)
Coverage of Biotech Equities -- MannKind, Novavax, Curis, Pharmacyclics, and Alexion Pharma
PR Newswire - Tue Mar 10, 8:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.88 (+0.09), PCYC: 256.98 (-0.77), NVAX: 8.51 (+0.09), ALXN: 188.19 (+1.41), MNKD: 4.90 (-0.09)
Curis closes equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:18PM CST
CRIS: 2.88 (+0.09)
Curis Announces Closing of Public Offering of Common Stock
GlobeNewswire - Mon Mar 02, 3:00PM CST
Curis, Inc. (Nasdaq:CRIS), announced today the closing of its previously announced public offering of common stock. Curis sold 25,090,908 shares of its common stock in the offering at a price to the public of $2.75 per share, including the exercise in full by the underwriters of their option to purchase an additional 3,272,727 shares of common stock at the public offering price. Curis received net proceeds of approximately $64.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.
CRIS: 2.88 (+0.09)
Curis prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:54AM CST
CRIS: 2.88 (+0.09)
Curis reports 4Q loss
Automated Insights - Tue Feb 24, 4:31PM CST
LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $5.7 million in its fourth quarter.
CRIS: 2.88 (+0.09)
Curis initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:05PM CST
CRIS: 2.88 (+0.09)
Curis EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 3:56PM CST
CRIS: 2.88 (+0.09)
A Look at the Latest Occurrences in the Biotechnology Sector: Special Research on China Biologic Products, Compugen, Curis, CytRx, and DBV Technologies
PR Newswire - Mon Feb 16, 7:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
CBPO: 99.67 (-0.84), CRIS: 2.88 (+0.09), DBVT: 25.66 (-0.01), CYTR: 5.21 (-0.06), CGEN: 7.10 (+0.01)
Strength Seen in Curis (CRIS): Stock Moves 9.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:25AM CST
Curis (CRIS) was a big mover last session, with shares rising over 9% on the day.
CRIS: 2.88 (+0.09), AFFX: 12.57 (-0.13)
Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting
GlobeNewswire - Wed Apr 22, 7:15AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced today data presented from in vitro and in vivo studies for CUDC-427, an antagonist of inhibitor of apoptosis (IAP) proteins, at the American Association for Cancer Research (AACR) 2015 Annual Meeting. CUDC-427 is being studied in a Phase 1 trial in patients with advanced solid tumors or lymphoma. Curis' collaborator, Aurigene Discovery Technologies Limited, also reported preclinical data on its interleukin-1 receptor association kinase-4 (IRAK-4) inhibitor program at AACR.
CRIS: 2.88 (+0.09), RDY: 56.58 (+0.30)
Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015
PR Newswire - Sat Apr 18, 7:00AM CDT
Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the American Associate of Cancer Research Annual Meeting (April 18-22 in Philadelphia, PA).
CRIS: 2.88 (+0.09)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 4:36PM CDT
MNK: 122.95 (-2.22), FARO: 44.64 (-0.93), MDVN: 128.88 (+0.29), CRIS: 2.88 (+0.09), E: 36.62 (+0.43), PH: 123.47 (+1.33), YOKU: 16.42 (-0.21), FXCM: 2.13 (+0.02), VSLR: 14.33 (+0.36), IGT: 19.88 (-0.02)
Biotech Stocks Technical Report -- Novavax, MannKind, Juno Therapeutics, Curis, and Ohr Pharma
PR Newswire - Thu Apr 16, 8:15AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.88 (+0.09), NVAX: 8.51 (+0.09), OHRP: 2.72 (+0.08), JUNO: 55.72 (-0.68), MNKD: 4.90 (-0.09)
Curis Announces Presentation of Data From CUDC-427 and IRAK-4 Programs at AACR Annual Meeting
GlobeNewswire - Tue Apr 14, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Curis scientists and its collaborator, Aurigene Discovery Technologies Limited, will present data from two programs at the Annual Meeting of American Association of Cancer Research (AACR) to be held April 18 - 22, 2015 in Philadelphia.
CRIS: 2.88 (+0.09), RDY: 56.58 (+0.30)
Curis' CUDC-907 an Orphan Drug for blood cancer
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 9:01AM CDT
CRIS: 2.88 (+0.09)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 8:18AM CDT
RESN: 3.77 (-0.06), HLF: 46.63 (-0.13), MHR: 2.34 (-0.07), NG: 3.56 (-0.07), CRIS: 2.88 (+0.09), GBSN: 4.98 (+1.44), QURE: 26.15 (-1.44), CYTX: 0.96 (-0.09), GAME: 6.85 (unch), BIND: 7.01 (-0.30), DGLY: 13.13 (+0.08), CAPN: 6.99 (-0.29)
Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Mon Apr 06, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead proprietary drug candidate, CUDC-907 for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL).
CRIS: 2.88 (+0.09)
Roth Capital Weighs In On 5 Biotech Stocks To Watch
TipRanks - at Seeking Alpha - Mon Apr 06, 4:02AM CDT
By Sarah Roden As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to "focus on names with definitive catalysts." Though the analyst rates 15 biotech stocks,...
CRIS: 2.88 (+0.09), GNVC: 2.86 (-0.11), CLDX: 28.95 (+1.08), BLRX: 2.12 (unch), KERX: 11.52 (-0.15)
Coverage of Biotech Equities -- MannKind, Novavax, Curis, Pharmacyclics, and Alexion Pharma
PR Newswire - Tue Mar 10, 8:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.88 (+0.09), PCYC: 256.98 (-0.77), NVAX: 8.51 (+0.09), ALXN: 188.19 (+1.41), MNKD: 4.90 (-0.09)
Curis closes equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:18PM CST
CRIS: 2.88 (+0.09)
Curis Announces Closing of Public Offering of Common Stock
GlobeNewswire - Mon Mar 02, 3:00PM CST
Curis, Inc. (Nasdaq:CRIS), announced today the closing of its previously announced public offering of common stock. Curis sold 25,090,908 shares of its common stock in the offering at a price to the public of $2.75 per share, including the exercise in full by the underwriters of their option to purchase an additional 3,272,727 shares of common stock at the public offering price. Curis received net proceeds of approximately $64.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.
CRIS: 2.88 (+0.09)
Curis prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:54AM CST
CRIS: 2.88 (+0.09)
Curis reports 4Q loss
Automated Insights - Tue Feb 24, 4:31PM CST
LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $5.7 million in its fourth quarter.
CRIS: 2.88 (+0.09)
Curis initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:05PM CST
CRIS: 2.88 (+0.09)
Curis EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 3:56PM CST
CRIS: 2.88 (+0.09)
A Look at the Latest Occurrences in the Biotechnology Sector: Special Research on China Biologic Products, Compugen, Curis, CytRx, and DBV Technologies
PR Newswire - Mon Feb 16, 7:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
CBPO: 99.67 (-0.84), CRIS: 2.88 (+0.09), DBVT: 25.66 (-0.01), CYTR: 5.21 (-0.06), CGEN: 7.10 (+0.01)
Strength Seen in Curis (CRIS): Stock Moves 9.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:25AM CST
Curis (CRIS) was a big mover last session, with shares rising over 9% on the day.
CRIS: 2.88 (+0.09), AFFX: 12.57 (-0.13)
